Download

Download Full Text (331 KB)

Description

Janus Kinase Inhibitors (JAKIs) are a recent advancement in Rheumatoid Arthritis (RA) treatment, offering an effective oral therapy option. However, adherence to JAKIs in RA patients is suboptimal compared to injectable options. Additionally, there is limited research on adherence to JAKIs among older adults in the United States. The study in question focused on examining JAKIs adherence in older RA patients enrolled in Medicare and identifying factors contributing to poor adherence.

Publication Date

2-21-2024

Relational Format

poster

Adherence to Janus Kinase Inhibitors Among Older Adults with Rheumatoid Arthritis Initiating New Treatment

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.